Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections

Journal of Clinical Microbiology

Volumn 48, Issue 5, 2010, Pages 1853-1858

  Jureen P ^a   Angeby K ^b   Sturegard E ^c   Chryssanthou, E ^b   Giske, C G ^b   Werngren, J ^a   Nordvall, M ^d   Johansson, A ^d   Kahlmeter, G ^e,f   Hoffner, S ^a   Schon T ^g  

^a Swedish Institute of Disease Control (SMI)   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e Vaxjo County Hospital   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

^g KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; STREPTOMYCIN; VIOMYCIN;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

AMINOGLYCOSIDES; ANTITUBERCULAR AGENTS; CULTURE MEDIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PEPTIDES, CYCLIC; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 77951864345     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00240-10     Document Type: Article

References (25)

1. American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
2. Chan, E. D., and M. D. Iseman. 2008. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr. Opin. Infect. Dis. 21:587-595.
3. Global Alliance for TB Drug Development. 2008. Special issue on TB drugs. Tuberculosis 88:85-167.
4. Heifets, L. 1988. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am. Rev. Respir. Dis. 137:1217-1222.
5. Hillemann, D., S. Rüsch-Gerdes, and E. Richter. 2009. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 47:1767-1772.
6. Holdiness, M. R. 1985. Chromatographic analysis of antituberculosis drugs in biological samples. J. Chromatogr. 340:321-359. (Pubitemid 15013668)
7. Iseman, M. D. 2000. A clinician's guide to tuberculosis. Lippincott Williams & Wilkins, Philadelphia, PA.
8. Jugheli, L., N. Bzekalva, P. de Rijk, K. Fissette, F. Portales, and L. Rigouts. 2009. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and close relation with mutations in the rrs gene. Antimicrob. Agents Chemother. 53:5064-5068.
9. Kahlmeter, G., D. F. Brown, F. W. Goldstein, A. P. MacGowan, J. W. Mouton, I. Odenholt, A. Rodloff, C. J. Soussy, M. Steinbakk, F. Soriano, and O. Stetsiouk. 2006. European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. Clin. Microbiol. Infect. 12:501-503.
10. Kashuba, A. D., A. N. Nafzinger, G. L. Drusano, and J. S. Bertino, Jr. 1999. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob. Agents Chemother. 43:623-629.
11. Kim, J. 2005. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur. Respir. J. 25:564-569.
12. Kim, S. J., M. A. Spinal, C. Abe, G. H. Bai, F. Boulahbal, L. Fattorin, C. Gilpin, S. Hoffner, K. M. Kam, N. Martin-Casabona, L. Rigouts, and V. Vincent. 2004. Is second-line anti-tuberculosis drug susceptibility testing reliable? Int. J. Tuber. Lung Dis. 8:1157-1158.
13. Krüüner, A., P. Jureen, S. Levina, S. Gebremichael, and S. Hoffner. 2003. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:2971-2973.
14. Reference deleted.
15. Maus, C. E., B. B. Plikaytis, and T. M. Shinnick. 2005. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:3192-3197.
16. McClatchy, J. K., W. Kanes, P. T. Davidson, and T. S. Moulding. 1977. Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin. Tubercle 58:29-34.
17. National Committee for Clinical Laboratory Standards. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard M24-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
18. Nuermberger, E., and J. Grosset. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. 23:243-255.
19. Peloquin, C. A. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. (Pubitemid 35252827)
20. Pyle, M. M. 1970. Ethambutol and viomycin. Med. Clin. North Am. 54:1317-1327.
21. Rastogi, N., V. Labrousse, and K. S. Goh. 1996. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr. Microbiol. 33:161-175.
22. Reference deleted.
23. Schön, T., P. Juréen, C. G. Giske, E. Chryssanthou, E. Sturegård, J. Werngren, G. Kahlmeter, S. E. Hoffner, and K. A. Angeby. 2009. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J. Antimicrob. Chemother. 64:786-793.
24. World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402. World Health Organization, Geneva, Switzerland.
25. World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/ 2008.392. World Health Organization, Geneva, Switzerland.